Strontium Chloride
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Strontium Chloride: From Unspecified Original Indication to Osteoarthritis
One-Sentence Summary
No original indication or licensed product record is currently available for Strontium chloride (DB13987) in this dataset. The TxGNN model predicts it may be effective for Osteoarthritis, with 1 clinical trial currently supporting this direction and no directly matched publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented (no original indications on file, no licensed products) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.28% |
| Evidence Level | L2 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this compound (MOA: Data Gap). Based on the mechanistic rationale extracted from the evidence pack, Sr²⁺ can substitute for Ca²⁺ in bone matrix, stimulating osteoblast proliferation/differentiation while inhibiting osteoclast activity — a mechanism well established for strontium-based compounds (e.g., strontium ranelate) in bone and joint disease.
The single supporting trial (NCT00954629) tested a topical strontium chloride hexahydrate formulation for knee osteoarthritis pain, which is mechanistically consistent with this pathway. However, this evidence pack’s drug entity is strontium chloride (DB13987), a different salt form from strontium ranelate, and it has not been confirmed whether the trial’s active ingredient is pharmacologically and formulation-wise identical to DB13987. This salt/formulation discrepancy must be resolved before the trial can be treated as direct supporting evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00954629 | Phase 3 | Unknown | 300 | 26-week, randomized, double-blind, placebo-controlled study of topical strontium chloride hexahydrate (2PX) vs. vehicle for knee osteoarthritis pain and physical function; result status not verified (trial marked “Unknown”). |
Literature Evidence
Currently no related literature available.
India Market Information
Strontium chloride (DB13987) is currently not marketed in India, and no license registrations are on record in this dataset.
Safety Considerations
Please refer to the package insert for safety information.
Note: Regulatory safety documentation (warnings, contraindications) for this compound has not yet been retrieved and is flagged as a blocking data gap for safety review.
Conclusion and Next Steps
Decision: Hold
Rationale: The only supporting trial has an unresolved (“Unknown”) completion status, and it is unconfirmed whether its active ingredient matches the exact salt form/formulation of DB13987. Combined with the absence of any safety documentation (warnings/contraindications), the candidate cannot yet clear even an initial safety screen (S1).
To proceed, the following is needed:
- Confirm whether the agent studied in NCT00954629 (topical strontium chloride hexahydrate) is pharmaceutically equivalent to DB13987
- Retrieve regulatory package insert / safety documentation (warnings, contraindications) — currently a blocking gap for S1 review
- Obtain a verified MOA reference from DrugBank to substantiate the mechanistic rationale
- Follow up on NCT00954629 for updated/completed results given its current “Unknown” status
- Deprioritize rank-2 prediction (“osteoarthritis susceptibility”) as it represents a genetic susceptibility marker, not a treatable disease phenotype
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.